Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain.
about
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic PotentialVoltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacologyA cell-permeant peptide corresponding to the cUBP domain of USP5 reverses inflammatory and neuropathic pain.Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief.Targeting voltage-gated calcium channels in neurological and psychiatric diseases.Surfen is a broad-spectrum calcium channel inhibitor with analgesic properties in mouse models of acute and chronic inflammatory pain.Regulation of the T-type Ca(2+) channel Cav3.2 by hydrogen sulfide: emerging controversies concerning the role of H2 S in nociception.Analgesic effect of a broad-spectrum dihydropyridine inhibitor of voltage-gated calcium channels.Recent advances in the development of T-type calcium channel blockers for pain intervention.A Cav3.2/Stac1 molecular complex controls T-type channel expression at the plasma membrane.[EXPRESS] Identification of interleukin-1 beta as a key mediator in the upregulation of Cav3.2-USP5 interactions in the pain pathwayInhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis.RETRACTED ARTICLE: TN-2 Exerts Anti-Inflammatory Effects on LPS-Induced Rat Dorsal Root Ganglion Neurons by Inhibiting TLR4-Mediated NF-κB and MAPK Pathways.Disrupting USP5/Cav3.2 interactions protects female mice from mechanical hypersensitivity during peripheral inflammationCRMP2 and voltage-gated ion channels: potential roles in neuropathic painCell-Type Specific Distribution of T-Type Calcium Currents in Lamina II Neurons of the Rat Spinal Cord
P2860
Q26781422-594697C3-88A4-4832-813E-2BE055F250B6Q37298134-1909D7CB-35AF-4550-A124-6BCFF3AE84E6Q38292647-D032E14B-19C1-49DF-BAF3-AE28C2033131Q38514549-80518158-3810-4D75-92B6-A5E7403B1728Q38626606-B028A0A6-2691-4C87-96BF-2DEBCA5D5A23Q38701037-97AF82C1-3D50-4506-A91C-EEB523A6BEB7Q38709498-11682536-E0C6-4133-ACE7-BB9973F6E005Q38842798-124E1648-9D0E-4C98-9EA7-7A6ABBC5BB87Q39154350-D80AEC0C-FC11-4347-9C48-AB5985BD735CQ39791514-44ECF905-AB95-4F87-B041-BEDA5AA0C5EDQ41443382-86FABB99-8E90-40FE-A2F9-E5F9FCE2040CQ42261427-B8C69FB3-F451-4488-938E-837974D04B2BQ48766906-CABA50E4-1C1E-4C3F-BB56-E588C00E24C9Q57810843-69C5B842-6549-4AC8-8D59-6D97750ADCDEQ58582878-FBD5833A-D9AC-4A15-AB17-0F33C867BE26Q58606217-6717F66D-B3A5-43F1-85F3-1094F2E9F9CB
P2860
Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Small organic molecule disrupt ...... ammatory and neuropathic pain.
@ast
Small organic molecule disrupt ...... ammatory and neuropathic pain.
@en
type
label
Small organic molecule disrupt ...... ammatory and neuropathic pain.
@ast
Small organic molecule disrupt ...... ammatory and neuropathic pain.
@en
prefLabel
Small organic molecule disrupt ...... ammatory and neuropathic pain.
@ast
Small organic molecule disrupt ...... ammatory and neuropathic pain.
@en
P2093
P2860
P1433
P1476
Small organic molecule disrupt ...... lammatory and neuropathic pain
@en
P2093
Agustin Garcia Caballero
Clare M Gladding
N Daniel Berger
Tom A Pfeifer
Vinicius M Gadotti
P2860
P2888
P356
10.1186/S12990-015-0011-8
P577
2015-03-14T00:00:00Z
P5875
P6179
1041163484